---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-024435"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T23:33:51.889010+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Avalo Q1 net loss $13.1M; cash $125M; Phase 2 HS data expected 2026

## Summary
- Net loss $13.1M ($1.25/shr) vs $121.3M in Q1 2024; prior-year included warrant and acquisition charges.
- Cash and equivalents $125M at March 31, 2025; runway into 2027, extendable to 2028 by delaying new indications.
- Phase 2 LOTUS trial for AVTX-009 in hidradenitis suppurativa on track; topline data expected in 2026.
- Mike Heffernan appointed Chairman of the Board.
- R&D expenses $9.1M (+$7M YoY) driven by LOTUS trial; G&A $5.5M (+$2.4M YoY) on stock compensation.

## SEC filing metadata
- accession: 0001628280-25-024435
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828025024435/0001628280-25-024435-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828025024435/avtx-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-024435
- JSON: https://secwatch.observer/filing/0001628280-25-024435.json
- Plain text: https://secwatch.observer/filing/0001628280-25-024435.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.